Amanpreet Kaur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Amanpreet Kaur has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Kanwaljit Chopra
Pharmacology Research Laboratory, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
3 shared publications - Nitin Bansal
Department of Pharmaceutical Sciences, Chaudhary Bansi Lal University, Bhiwani, India
3 shared publications - Rishabh Chaudhary
Department of Pharmacology, M. M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, India
3 shared publications - Seema Bansal
Department of Pharmacology, M. M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, India
3 shared publications - Geeta Aggarwal
School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
2 shared publications Anjali Kumari
School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, India
1 shared publication
Latest Publications
- 18 September 2026
- Published by Chitkara University Publications in Journal of Pharmaceutical Technology, Research and Management
- Vol. 14 (1) , 74-86
Epigenetic Remodeling in Alzheimer’s Disease: Mechanistic Insights and Therapeutic Opportunities
Background: Alzheimer’s Disease (AD) is the most prevalent neurodegenerative disorder and a leading cause of dementia, involving the gradual loss of cognitive function, memory, and neurons. While the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs), caused by hyperphosphorylation of the protein tau, continue to be recognized as hallmarks of AD pathology, emerging evidence suggests that epigenetic dysregulation plays a crucial role in disease initiation and progression. Purpose: The current review highlights the role of epigenetic remodeling in AD pathogenesis, emerging biomarkers associated with epigenetics, therapeutic strategies, and translational challenges. Methods: This narrative review was conducted through a structured literature search of PubMed, Scopus, and Web of Science databases following the PRISMA framework. Relevant studies on epigenetic mechanisms, biomarkers, and therapeutic strategies in AD were screened and critically reviewed. Results: Epigenetic mechanisms, including DNA methylation, histone modifications, and non-coding RNA-mediated regulation, affect gene expression without changing the underlying DNA sequence and serve as a critical interface between genetic susceptibility, aging, and environment. Aberrant DNA methylation, changes in histone acetylation, methylation, phosphorylation, and ubiquitination, along with the dysregulation of microRNAs and long noncoding RNA, all play a role in amyloidosis, tauopathy, inflammation, oxidative damage, synaptic dysfunction, and neuronal loss. Additionally, several biomarkers related to epigenetics such as ANK1 methylation, miR-29a/b, miR-107, miR-132, miR-146a, and BACE1-AS have been discovered as potential disease biomarkers. Epigenetic therapeutics involving histone deacetylase inhibitors, DNA methyltransferase regulators, sirtuin-targeting agents, and RNA-based therapeutics have demonstrated neuroprotective effects in preclinical models of AD. Nevertheless, there are certain obstacles that limit their utility, such as insufficient blood-brain barrier (BBB) permeability, off-target effects, and poor clinical translation. Conclusion: Advancing our understanding of the epigenetic landscape of AD may facilitate the development of precision diagnostics and disease-modifying therapies.
- 18 September 2026
- Published by Chitkara University Publications in Journal of Pharmaceutical Technology, Research and Management
- Vol. 14 (1) , 74-86
Epigenetic Remodeling in Alzheimer’s Disease: Mechanistic Insights and Therapeutic Opportunities
Background: Alzheimer’s Disease (AD) is the most prevalent neurodegenerative disorder and a leading cause of dementia, involving the gradual loss of cognitive function, memory, and neurons. While the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs), caused by hyperphosphorylation of the protein tau, continue to be recognized as hallmarks of AD pathology, emerging evidence suggests that epigenetic dysregulation plays a crucial role in disease initiation and progression. Purpose: The current review highlights the role of epigenetic remodeling in AD pathogenesis, emerging biomarkers associated with epigenetics, therapeutic strategies, and translational challenges. Methods: This narrative review was conducted through a structured literature search of PubMed, Scopus, and Web of Science databases following the PRISMA framework. Relevant studies on epigenetic mechanisms, biomarkers, and therapeutic strategies in AD were screened and critically reviewed. Results: Epigenetic mechanisms, including DNA methylation, histone modifications, and non-coding RNA-mediated regulation, affect gene expression without changing the underlying DNA sequence and serve as a critical interface between genetic susceptibility, aging, and environment. Aberrant DNA methylation, changes in histone acetylation, methylation, phosphorylation, and ubiquitination, along with the dysregulation of microRNAs and long noncoding RNA, all play a role in amyloidosis, tauopathy, inflammation, oxidative damage, synaptic dysfunction, and neuronal loss. Additionally, several biomarkers related to epigenetics such as ANK1 methylation, miR-29a/b, miR-107, miR-132, miR-146a, and BACE1-AS have been discovered as potential disease biomarkers. Epigenetic therapeutics involving histone deacetylase inhibitors, DNA methyltransferase regulators, sirtuin-targeting agents, and RNA-based therapeutics have demonstrated neuroprotective effects in preclinical models of AD. Nevertheless, there are certain obstacles that limit their utility, such as insufficient blood-brain barrier (BBB) permeability, off-target effects, and poor clinical translation. Conclusion: Advancing our understanding of the epigenetic landscape of AD may facilitate the development of precision diagnostics and disease-modifying therapies.
- 16 March 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (8) , 12539-12557
Fabrication and characterization of prednisolone acetate-loaded electrospun mucoadhesive nanofibers for treatment of oral lichen planus
Oral lichen planus (OLP), a chronic inflammatory disease affecting the stratified squamous epithelium of oral mucosa (mucositis), presents treatment challenges due to rapid washout of conventional topical gels. This study developed prednisolone acetate-loaded mucoadhesive electrospun nanofibers using PVP K90/Eudragit RS100 via Super ES-3 technology to enhance drug retention and therapeutic efficacy. Nanofibers exhibited uniform morphology (diameter ranging from185 ± 0.3 nm to 704 ± 0.3 nm), neutral surface pH (7.4 ± 0.1), and superior mucoadhesion of 0.03N and bond strength of 0.455 Nmm2. FTIR confirmed polymer-drug compatibility and XRD studies revealed crystalline state of drug in nanofibers. In vitro release from prednisolone acetate-loaded nanofibers followed zero-order kinetics (r2 = 0.999, RMSE = 1.02%, 90.21% Q₁₂ₕ), ideal for sustained delivery vis a vis. prednisolone acetate dispersion that followed Korsmeyer-Peppas model (r2 = 0.962, RMSE = 3.99, 51.34% Q12h). In vivo evaluations using 4% SDS-induced mucosal irritation model in Wistar rats shown irritation score of 4.333 ± 0.58 in disease control, nanofibers achieved near-complete resolution (score 1.000 ± 0.58, equivalent to vehicle p = 0.7538), significantly outperforming marketed formulation (3.000 ± 0.58, p = 0.0015; using one-way ANOVA F = 45.2, p < 0.0001). Histopathology confirmed superiority with no signs of irritation or tissue damage of the oral mucosa showing normalized rete ridges and minimal inflammation. These findings demonstrate mucoadhesive nanofibers as a promising localized delivery system for OLP, providing sustained prednisolone acetate release, prolonged buccal retention of 7 h, and superior therapeutic outcomes while minimizing systemic corticosteroid exposure.
- 16 March 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (8) , 12539-12557
Fabrication and characterization of prednisolone acetate-loaded electrospun mucoadhesive nanofibers for treatment of oral lichen planus
Oral lichen planus (OLP), a chronic inflammatory disease affecting the stratified squamous epithelium of oral mucosa (mucositis), presents treatment challenges due to rapid washout of conventional topical gels. This study developed prednisolone acetate-loaded mucoadhesive electrospun nanofibers using PVP K90/Eudragit RS100 via Super ES-3 technology to enhance drug retention and therapeutic efficacy. Nanofibers exhibited uniform morphology (diameter ranging from185 ± 0.3 nm to 704 ± 0.3 nm), neutral surface pH (7.4 ± 0.1), and superior mucoadhesion of 0.03N and bond strength of 0.455 Nmm2. FTIR confirmed polymer-drug compatibility and XRD studies revealed crystalline state of drug in nanofibers. In vitro release from prednisolone acetate-loaded nanofibers followed zero-order kinetics (r2 = 0.999, RMSE = 1.02%, 90.21% Q₁₂ₕ), ideal for sustained delivery vis a vis. prednisolone acetate dispersion that followed Korsmeyer-Peppas model (r2 = 0.962, RMSE = 3.99, 51.34% Q12h). In vivo evaluations using 4% SDS-induced mucosal irritation model in Wistar rats shown irritation score of 4.333 ± 0.58 in disease control, nanofibers achieved near-complete resolution (score 1.000 ± 0.58, equivalent to vehicle p = 0.7538), significantly outperforming marketed formulation (3.000 ± 0.58, p = 0.0015; using one-way ANOVA F = 45.2, p < 0.0001). Histopathology confirmed superiority with no signs of irritation or tissue damage of the oral mucosa showing normalized rete ridges and minimal inflammation. These findings demonstrate mucoadhesive nanofibers as a promising localized delivery system for OLP, providing sustained prednisolone acetate release, prolonged buccal retention of 7 h, and superior therapeutic outcomes while minimizing systemic corticosteroid exposure.
- Open Access
- 23 February 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1) , 10
Nanocarrier armor for siRNA delivery to address fracture risk in osteoporosis
Osteoporosis is a metabolic disorder of the bones that is identified by progressive structural degradation, decreased bone density, and raised the risk of fractures, which ultimately impacting the quality of life of patients. Its complex pathogenesis involves bone breakdown, reduced bone formation, and insufficient vascularization. Traditional treatments struggle to comprehensively tackle this multifaceted challenge. The existing therapies are non-specific and offer limited efficacy and also have shown adverse effects when used for long term. Therefore, the quest for therapeutic medications devoid of adverse effects is an essential and pressing need. The disease’s rising global incidence highlights the need for more effective treatments, prompting ongoing research into novel targets and therapies. There is a growing enthusiasm for small interfering RNA (siRNA) nanotherapeutics, indicating a promising future for these interdisciplinary approach-based modalities that integrate the fundamental principles of molecular biology, precision medicine, and nanotechnology. These therapies are limited by certain challenges viz., cell membrane permeability, degradation by nucleases, off target effects, endosomal escape etc. Extensive research on development of nanocarrier armor has helped overcome the delivery challenges of siRNA. These advancements offer targeted gene silencing of specific molecular mechanisms involved in bone remodeling and fracture, thereby providing a ray of hope for osteoporosis treatment. This review explores the role of signaling pathways, challenges of existing conventional therapies and potential therapeutic avenues for advanced therapies with special emphasis on siRNA delivery in the osteoporosis treatment. Graphical Abstract
- 23 February 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1) , 10
Open AccessNanocarrier armor for siRNA delivery to address fracture risk in osteoporosis
Osteoporosis is a metabolic disorder of the bones that is identified by progressive structural degradation, decreased bone density, and raised the risk of fractures, which ultimately impacting the quality of life of patients. Its complex pathogenesis involves bone breakdown, reduced bone formation, and insufficient vascularization. Traditional treatments struggle to comprehensively tackle this multifaceted challenge. The existing therapies are non-specific and offer limited efficacy and also have shown adverse effects when used for long term. Therefore, the quest for therapeutic medications devoid of adverse effects is an essential and pressing need. The disease’s rising global incidence highlights the need for more effective treatments, prompting ongoing research into novel targets and therapies. There is a growing enthusiasm for small interfering RNA (siRNA) nanotherapeutics, indicating a promising future for these interdisciplinary approach-based modalities that integrate the fundamental principles of molecular biology, precision medicine, and nanotechnology. These therapies are limited by certain challenges viz., cell membrane permeability, degradation by nucleases, off target effects, endosomal escape etc. Extensive research on development of nanocarrier armor has helped overcome the delivery challenges of siRNA. These advancements offer targeted gene silencing of specific molecular mechanisms involved in bone remodeling and fracture, thereby providing a ray of hope for osteoporosis treatment. This review explores the role of signaling pathways, challenges of existing conventional therapies and potential therapeutic avenues for advanced therapies with special emphasis on siRNA delivery in the osteoporosis treatment. Graphical Abstract
- 19 February 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 17 (5) , 2410-2429
Fructooligosaccharide ameliorates estrogen–gut–microbiome–brain axis dysfunction in estrogen-deficient rats
Reduced levels of circulating gonadal hormones in post-menopausal women can negatively affect various physiological functions, including brain and gut deficits. There is an urgent need to find novel strategies to mitigate estrogen–gut–microbiome–brain axis (EGMBA) dysfunction. This study aimed to investigate the effect of fructooligosaccharide (FOS), a non-digestible prebiotic fiber, on estrogen deficiency-induced alterations in the EGMBA using an ovariectomized (OVX) rat model. Adult female SD rats were bilaterally OVX to induce estrogen deficiency and associated EGMBA dysfunction. Rats were administered FOS (50 mg kg−1 p.o.−1) for 28 consecutive days. To assess EGMBA dysfunction, after 28 days, we performed behavioral tests, biochemical estimations (oxidative stress), molecular estimations (inflammatory markers via ELISA), gene expression analysis (HPA axis, monoamine neurotransmission, apoptosis, gut microbiota alterations, & gut barrier integrity via RT-PCR/qPCR), and histopathological analysis. Administration of FOS significantly improved behavioral outcomes (reducing anxiety and depression, and improving memory). FOS also attenuates oxidative stress and inflammatory markers. FOS regulates apoptosis (upregulation of BCL-2 and downregulation of Bax), HPA axis functioning (corticosterone, GR, MR, & CRH), and monoamine neurotransmission (MAO-A & COMT) in the hippocampus of OVX rats. FOS also promoted healthy cell growth and prevented apoptosis. Additionally, FOS restored gut microbial eubiosis, improved mucus secretion (MUC-2), preserved tight junction protein expression (Lipocalin-2, Claudin, & TLR-4), and maintained the colon microstructure. FOS exerts multifaceted protective effects on the EGMBA by modulating gut and brain functions. These findings support its potential as a non-hormonal therapeutic approach for managing postmenopausal complications.
- 19 February 2026
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 17 (5) , 2410-2429
Fructooligosaccharide ameliorates estrogen–gut–microbiome–brain axis dysfunction in estrogen-deficient rats
Reduced levels of circulating gonadal hormones in post-menopausal women can negatively affect various physiological functions, including brain and gut deficits. There is an urgent need to find novel strategies to mitigate estrogen–gut–microbiome–brain axis (EGMBA) dysfunction. This study aimed to investigate the effect of fructooligosaccharide (FOS), a non-digestible prebiotic fiber, on estrogen deficiency-induced alterations in the EGMBA using an ovariectomized (OVX) rat model. Adult female SD rats were bilaterally OVX to induce estrogen deficiency and associated EGMBA dysfunction. Rats were administered FOS (50 mg kg−1 p.o.−1) for 28 consecutive days. To assess EGMBA dysfunction, after 28 days, we performed behavioral tests, biochemical estimations (oxidative stress), molecular estimations (inflammatory markers via ELISA), gene expression analysis (HPA axis, monoamine neurotransmission, apoptosis, gut microbiota alterations, & gut barrier integrity via RT-PCR/qPCR), and histopathological analysis. Administration of FOS significantly improved behavioral outcomes (reducing anxiety and depression, and improving memory). FOS also attenuates oxidative stress and inflammatory markers. FOS regulates apoptosis (upregulation of BCL-2 and downregulation of Bax), HPA axis functioning (corticosterone, GR, MR, & CRH), and monoamine neurotransmission (MAO-A & COMT) in the hippocampus of OVX rats. FOS also promoted healthy cell growth and prevented apoptosis. Additionally, FOS restored gut microbial eubiosis, improved mucus secretion (MUC-2), preserved tight junction protein expression (Lipocalin-2, Claudin, & TLR-4), and maintained the colon microstructure. FOS exerts multifaceted protective effects on the EGMBA by modulating gut and brain functions. These findings support its potential as a non-hormonal therapeutic approach for managing postmenopausal complications.
- 24 July 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (1) , 1029-1047
Gut microbiota metabolic axis dysfunction in estrogen deficient stressed rats
Gut dysbiosis, an imbalance in the gut microbiota (GM), has emerged as a key factor contributing to metabolic dysfunction following estrogen deficiency in menopause. Disruptions in gut microbial composition, triggered by hormonal imbalances and chronic stress, can exacerbate metabolic disturbances, such as obesity, dyslipidemia, and diabetes etc. Thus strategies, which modulates gut dysbiosis may proves important for the treatment of metabolic dysfunctions in postmenopausal state. However, the physiological, biochemical and molecular changes occurring due to estrogen deficiency and stress are yet to be elucidated. Thus, aim of the present study was to develop a pre-clinical model to investigate the effect of estrogen deficiency and chronic unpredictable mild stress (CUMS) alone and in combination on GM alterations and associated metabolic dysfunction. Ovariectomized (OVX) rats were subjected to CUMS for 28 days to induce metabolic alterations and gut dysbiosis. Estrogen deficiency and chronic stress altered physiological changes, adiposity, and anthropometric markers. Furthermore, OVX and CUMS elevated oxidative stress in liver and colon and increased inflammatory markers as detected in serum, Liver, and colon. This, in turn, led to damage of the mucosal layer and disruption of tight junction proteins. OVX and CUMS also caused gut dysbiosis, as indicated by an increased ratio of pathogenic to beneficial gut bacterial populations. Histopathological examination showed colon and liver tissues damage in OVX, CUMS, and OVX + CUMS group rats. OVX and CUMS, both individually and synergistically, contributed to the development of gut and metabolic dysfunction, collectively referred to as gut-metabolic axis dysfunction in OVX-stressed rats.
- 24 July 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (1) , 1029-1047
Gut microbiota metabolic axis dysfunction in estrogen deficient stressed rats
Gut dysbiosis, an imbalance in the gut microbiota (GM), has emerged as a key factor contributing to metabolic dysfunction following estrogen deficiency in menopause. Disruptions in gut microbial composition, triggered by hormonal imbalances and chronic stress, can exacerbate metabolic disturbances, such as obesity, dyslipidemia, and diabetes etc. Thus strategies, which modulates gut dysbiosis may proves important for the treatment of metabolic dysfunctions in postmenopausal state. However, the physiological, biochemical and molecular changes occurring due to estrogen deficiency and stress are yet to be elucidated. Thus, aim of the present study was to develop a pre-clinical model to investigate the effect of estrogen deficiency and chronic unpredictable mild stress (CUMS) alone and in combination on GM alterations and associated metabolic dysfunction. Ovariectomized (OVX) rats were subjected to CUMS for 28 days to induce metabolic alterations and gut dysbiosis. Estrogen deficiency and chronic stress altered physiological changes, adiposity, and anthropometric markers. Furthermore, OVX and CUMS elevated oxidative stress in liver and colon and increased inflammatory markers as detected in serum, Liver, and colon. This, in turn, led to damage of the mucosal layer and disruption of tight junction proteins. OVX and CUMS also caused gut dysbiosis, as indicated by an increased ratio of pathogenic to beneficial gut bacterial populations. Histopathological examination showed colon and liver tissues damage in OVX, CUMS, and OVX + CUMS group rats. OVX and CUMS, both individually and synergistically, contributed to the development of gut and metabolic dysfunction, collectively referred to as gut-metabolic axis dysfunction in OVX-stressed rats.
- 27 January 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 26 (1) , 1-23
Biosimilars: A Critical Review of Development, Regulatory Landscape, and Clinical Implications
The biopharmaceutical industry has witnessed significant growth in the development and approval of biosimilars. These biosimilars aim to provide cost-effec
- 27 January 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 26 (1) , 1-23
Biosimilars: A Critical Review of Development, Regulatory Landscape, and Clinical Implications
The biopharmaceutical industry has witnessed significant growth in the development and approval of biosimilars. These biosimilars aim to provide cost-effec
- Open Access
- 16 September 2023
- Published by Elsevier in Asian Journal of Pharmaceutical Sciences
- Vol. 18 (5) , 100845
The emerging potential of siRNA nanotherapeutics in treatment of arthritis
- 16 September 2023
- Published by Elsevier in Asian Journal of Pharmaceutical Sciences
- Vol. 18 (5) , 100845
Open AccessThe emerging potential of siRNA nanotherapeutics in treatment of arthritis